Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer

In a phase I dose escalation/expansion study, use of the HER3-DXd antibody drug conjugate showed clinical activity in EGFR TKI-resistant, EGFR-mutant non–small cell lung cancer, presenting a future option for drug-resistant cancers.

[1]  S. Ou,et al.  Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. , 2021 .

[2]  P. Jänne,et al.  Thirty Years of HER3: From Basic Biology to Therapeutic Interventions , 2021, Clinical Cancer Research.

[3]  S. Chandarlapaty,et al.  Unlocking the potential of antibody–drug conjugates for cancer therapy , 2021, Nature Reviews Clinical Oncology.

[4]  T. Forshew,et al.  Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC) , 2020, Journal for ImmunoTherapy of Cancer.

[5]  P. Janne,et al.  Abstract 5192: EGFR inhibition enhances the cellular uptake and antitumor activity of the novel HER3 antibody drug conjugate U3-1402 , 2020 .

[6]  K. Suresh,et al.  Pulmonary toxicity of systemic lung cancer therapy , 2020, Respirology.

[7]  Y. Bang,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. , 2020, The New England journal of medicine.

[8]  L. Sequist,et al.  Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. , 2020, The Lancet. Oncology.

[9]  D. Pe’er,et al.  Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer , 2020, Clinical Cancer Research.

[10]  K. Hansen,et al.  Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer. , 2019, Lung cancer.

[11]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.

[12]  Ying Cheng,et al.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.

[13]  M. Tiseo,et al.  Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives. , 2019, Critical reviews in oncology/hematology.

[14]  M. Murakami,et al.  A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization , 2019, Clinical Cancer Research.

[15]  Y. Matsumura,et al.  U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer , 2019, Molecular Cancer Therapeutics.

[16]  M. Westphal,et al.  EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients , 2019, Scientific Reports.

[17]  H. Iwata,et al.  Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  T. Agatsuma,et al.  The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. , 2019, Chemical & pharmaceutical bulletin.

[19]  R. Rosell,et al.  EGFR first- and second-generation TKIs—there is still place for them in EGFR -mutant NSCLC patients , 2018 .

[20]  K. Nishio,et al.  An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC , 2018, Oncogene.

[21]  J. Barrett,et al.  Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  J. Barrett,et al.  Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  M. Ahn,et al.  Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  B. Han,et al.  Efficacy of pemetrexed-based regimens in advanced non–small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review , 2018, OncoTargets and therapy.

[25]  J. Shih,et al.  Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer , 2018, Molecular Cancer.

[26]  B. Goh,et al.  Third generation EGFR TKIs: current data and future directions , 2018, Molecular Cancer.

[27]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[28]  Li Wu,et al.  Prognostic significance of HER3 in patients with malignant solid tumors , 2017, Oncotarget.

[29]  J. Hung,et al.  The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy , 2017, BMC Pharmacology and Toxicology.

[30]  M. Tiseo,et al.  Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance. , 2016, Translational lung cancer research.

[31]  K. Wang,et al.  The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis , 2016, Oncotarget.

[32]  T. Agatsuma,et al.  Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity , 2016, Cancer science.

[33]  T. Agatsuma,et al.  DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 , 2016, Clinical Cancer Research.

[34]  M. Kris,et al.  Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  V. Grantcharova,et al.  Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.

[36]  H. Sasaki,et al.  ErbB3 mRNA expression correlated with specific clinicopathologic features of Japanese lung cancers. , 2008, The Journal of surgical research.